EMEA COMMITTEE
May 1st, 2002
BY KEITH NUTHALLEMEA's Committee for Proprietary Medicinal Products has given a positive opinion on a range of insulin medicines, namely Actrapid, Actraphane, Insulatard, Mixtard, Monotard, Protophane, Ultratard and Velosulin. The committee also began risk-benefit reviews of gatifloxacin, (containing Bonoq, Crispin, Urobonoq, Urocrispin and associated product names) and nimesulide containing medicinal products (Aulin, Mesulide, Nimed and associated product names). These studies follow safety and efficacy concerns raised by Belgium and Finland. The committee also ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.